| Name | Title | Contact Details |
|---|
Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company`s current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012. EXPAREL and two other products have utilized the Pacira proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Fairhaven Crowne is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nars Cosmetics, Inc, division of Shiseido Cosmetics America Ltd. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New York, NY. To find more information about Nars Cosmetics, Inc, division of Shiseido Cosmetics America Ltd., please visit www.narscosmetics.com
Since 1914, Pana Community Hospital has been a place for quality health care. Our employees, medical staff, board of directors and management continue to strengthen and expand our hospital and its’ services. We are committed to your health care future, making our hospital a place you can count on. You can be sure our focus is on today and tomorrow…always striving to bring you quality health care close to home! Our Mission is to be a leading partner in assuring community-based quality Healthcare.
Heart Force Medical Inc. (HFM), a private company, has invented and has patents pending for the digital Ballistocardiograph (dBG(TM)). The dBG 300, which is already approved in Canada and the United States, captures the movement of the heart during each cardiac cycle (heart beat). This movement (acceleration and force) is sensed by an accelerometer aligned to the three principal axes and displayed on a computer screen using HFM's proprietary software. Preliminary evaluation has determined that a 10-30 second recording of the dBG waveform is sufficient for a detailed analysis of cardiac performance. The Heart Force dBG 300 device is a non-invasive, standalone, portable unit and contains sophisticated digital sensors and proprietary software.